Jiangxi Fushine Pharmaceutical Co Ltd Cash Flow Conversion Efficiency
Jiangxi Fushine Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Jiangxi Fushine Pharmaceutical Co Ltd (300497) has a cash flow conversion efficiency ratio of 0.008x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥18.31 Million ≈ $2.68 Million USD) by net assets (CN¥2.17 Billion ≈ $317.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Jiangxi Fushine Pharmaceutical Co Ltd (2011–2025)
Cash flow conversion efficiency of Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2025. This chart illustrates how Jiangxi Fushine Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 300497 live share price for real-time trading data and today's change.
Jiangxi Fushine Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained
Jiangxi Fushine Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Jiangxi Fushine Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jiangxi Fushine Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Also see how much is Jiangxi Fushine Pharmaceutical Co Ltd worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
|
0.015x |
|
Five Star Bancorp
NASDAQ:FSBC
|
0.050x |
|
Taiyuan Heavy Industry Co Ltd
SHG:600169
|
0.080x |
|
Smartgroup Corporation Ltd
AU:SIQ
|
0.253x |
|
Medical Properties Trust, Inc.
NYSE:MPT
|
-0.003x |
|
E2E Networks Limited
NSE:E2E
|
0.020x |
|
Jiangsu Gian Technology Co Ltd
SHE:300709
|
0.215x |
|
MAC Copper Ltd
AU:MAC
|
0.243x |
Annual Cash Flow Conversion Efficiency for Jiangxi Fushine Pharmaceutical Co Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of Jiangxi Fushine Pharmaceutical Co Ltd from 2011 to 2025. Review Jiangxi Fushine Pharmaceutical Co Ltd (300497) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.20 Billion ≈ $321.96 Million |
CN¥62.67 Million ≈ $9.17 Million |
0.028x | -66.95% |
| 2024-12-31 | CN¥2.18 Billion ≈ $318.55 Million |
CN¥187.64 Million ≈ $27.46 Million |
0.086x | +428.84% |
| 2023-12-31 | CN¥2.47 Billion ≈ $361.55 Million |
CN¥-64.76 Million ≈ $-9.48 Million |
-0.026x | +41.66% |
| 2022-12-31 | CN¥2.69 Billion ≈ $393.58 Million |
CN¥-120.85 Million ≈ $-17.68 Million |
-0.045x | -280.87% |
| 2021-12-31 | CN¥2.91 Billion ≈ $426.02 Million |
CN¥72.32 Million ≈ $10.58 Million |
0.025x | -80.20% |
| 2020-12-31 | CN¥3.05 Billion ≈ $445.98 Million |
CN¥382.35 Million ≈ $55.95 Million |
0.125x | -43.29% |
| 2019-12-31 | CN¥1.53 Billion ≈ $223.52 Million |
CN¥337.91 Million ≈ $49.45 Million |
0.221x | +44.20% |
| 2018-12-31 | CN¥1.15 Billion ≈ $167.80 Million |
CN¥175.91 Million ≈ $25.74 Million |
0.153x | -29.62% |
| 2017-12-31 | CN¥966.71 Million ≈ $141.46 Million |
CN¥210.72 Million ≈ $30.84 Million |
0.218x | -9.34% |
| 2016-12-31 | CN¥784.17 Million ≈ $114.75 Million |
CN¥188.53 Million ≈ $27.59 Million |
0.240x | +93.69% |
| 2015-12-31 | CN¥596.21 Million ≈ $87.24 Million |
CN¥74.01 Million ≈ $10.83 Million |
0.124x | +12.02% |
| 2014-12-31 | CN¥283.26 Million ≈ $41.45 Million |
CN¥31.39 Million ≈ $4.59 Million |
0.111x | -55.50% |
| 2013-12-31 | CN¥229.76 Million ≈ $33.62 Million |
CN¥57.22 Million ≈ $8.37 Million |
0.249x | -27.25% |
| 2012-12-31 | CN¥184.60 Million ≈ $27.01 Million |
CN¥63.20 Million ≈ $9.25 Million |
0.342x | +22.08% |
| 2011-12-31 | CN¥120.52 Million ≈ $17.64 Million |
CN¥33.80 Million ≈ $4.95 Million |
0.280x | -- |
About Jiangxi Fushine Pharmaceutical Co Ltd
Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. It offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersi… Read more